0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Exhibition > 2nd Annual Infectious Disease Diagnostics and Point-Of-Care Testing
  1. 2nd Annual Infectious Disease Diagnostics and Point-Of-Care Testing

    1. March 11th-12th, 2021, EST
    2. Virtual
    3. Prajwal Paudel and more
    We are the Gold Sponsor for this virtual conference. Don’t miss our talk on March 11th @11:10am EST.
  2. The Diagnostics sector has emerged as a prominent game changer in healthcare, because of many technological advancements taking place within the field. As diagnostics is a key for making the treatment decisions, it needs to be quicker, précised, and accurate.

     

    Point-of-care testing (POCT) is a growing testing. Today, you may see POCT in a hospital with handheld gadgets or small testers in emergency department, extensive care setting, popular clinical wards, and imaging facilities. And market analyses that the world is moving from critical laboratory testing to testing for quick and accurate results at the patient's point of care.

     

    In the era of improved diagnostics, our 2nd Annual Virtual Event on Infectious Disease Diagnostics and Point-Of-Care Testing will serve as a networking place for Diagnostics professional, Industrial specialists, and solution providers to address the rising innovation in its discipline and the way it can be used as disease prevention tool.

    Sponsored by leading manufacturer of recombinant proteins and other critical reagents – ACROBiosystems.

     

    ACROBio’s talk

    Day 1: March 11th @11:10am EST

     

    Talk Tittle: Critical needs of reagents and assay kits to fight COVID-19 and SARS-CoV-2 variants

     

    Highlights:

    · ACROBiosystems has mobilized resources to generate high quality SARS-CoV-2 antigens, antibody and ELISA Kits.

    · The quality of antibody and antigens significantly affect the performance of diagnostic kits and therapeutics derived.

    · The Superstable Spike Trimer available at 90% purity and homogeneity enables development and evaluation for high  performance serological test kits and therapeutics.

    · We have also developed Neutralization Test kit with performance on par with FDA approved kit.

    · Our pre-couple magnetic beads reduce time and provide stability tested products for antibody screening and characterization studies.

    · With emerging variants in UK, S Africa and S. America posing threat to existing vaccines and therapeutics, ACROBiosystem is continually updating product line to support both research and clinical development efforts.

     

    Speaker: Prajwal Paudel, Ph.D.

    Product Development Scientist at ACROBiosystems Inc.

New & Hot Products


This web search service is supported by Google Inc.

totop